AI Article Synopsis

  • The study explores the role of microRNA-155 (miR-155) in rheumatoid arthritis (RA), specifically how its increased expression may hinder monocyte polarization into anti-inflammatory macrophages.
  • Researchers tested the therapeutic effects of antagomiR-155-5p, a molecule designed to inhibit miR-155, using PEGylated liposomes in two mouse models of RA.
  • Results showed that injecting these liposomes reduced arthritis symptoms and improved the differentiation of bone marrow monocytes into anti-inflammatory macrophages, indicating a potential treatment strategy for RA in humans.

Article Abstract

Objective: We previously reported an increased expression of microRNA-155 (miR-155) in the blood monocytes of patients with rheumatoid arthritis (RA) that could be responsible for impaired monocyte polarization to anti-inflammatory M2-like macrophages. In this study, we employed two preclinical models of RA, collagen-induced arthritis and K/BxN serum transfer arthritis, to examine the therapeutic potential of antagomiR-155-5p entrapped within PEGylated (polyethylene glycol [PEG]) liposomes in resolution of arthritis and repolarization of monocytes towards the anti-inflammatory M2 phenotype.

Methods: AntagomiR-155-5p or antagomiR-control were encapsulated in PEG liposomes of 100 nm in size and -10 mV in zeta potential with high antagomiR loading efficiency (above 80%). Mice were injected intravenously with 1.5 nmol/100 μL PEG liposomes containing antagomiR-155-5p or control after the induction of arthritis.

Results: We demonstrated the biodistribution of fluorescently tagged PEG liposomes to inflamed joints one hour after the injection of fluorescently tagged PEG liposomes, as well as the liver's subsequent accumulation after 48 hours, indicative of hepatic clearance, in mice with arthritis. The injection of PEG liposomes containing antagomiR-155-5p decreased arthritis score and paw swelling compared with PEG liposomes containing antagomiR-control or the systemic delivery of free antagomiR-155-5p. Moreover, treatment with PEG liposomes containing antagomiR-155-5p led to the restoration of bone marrow monocyte defects in anti-inflammatory macrophage differentiation without any significant functional change in other immune cells, including splenic B and T cells.

Conclusion: The injection of antagomiR-155-5p encapsulated in PEG liposomes allows the delivery of small RNA to monocytes and macrophages and reduces joint inflammation in murine models of RA, providing a promising strategy in human disease.

Download full-text PDF

Source
http://dx.doi.org/10.1002/art.42665DOI Listing

Publication Analysis

Top Keywords

peg liposomes
32
liposomes antagomir-155-5p
12
liposomes
9
arthritis
8
preclinical models
8
rheumatoid arthritis
8
peg
8
encapsulated peg
8
fluorescently tagged
8
tagged peg
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!